| Mrs Kelli Renee White, FNP-BC | |
|
1924 Pine St, Suite 401c, Abilene, TX 79601-2451 | |
| (325) 670-4020 | |
| Not Available |
| Full Name | Mrs Kelli Renee White |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 1924 Pine St, Abilene, Texas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538304266 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 718636 (Texas) | Primary |
| Entity Name | Neurosurgery Associates Of West Texas, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417142233 PECOS PAC ID: 1052409521 Enrollment ID: O20071116000194 |
News Archive
Glenmark Pharmaceuticals S.A, a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India, announced today that it has entered into an agreement with Sanofi to grant Sanofi a license for the development and commercialization of GBR 500, a novel monoclonal antibody for the treatment of Crohn's Disease and other inflammatory conditions.
A potential new drug for lung cancer has eliminated tumours in 50% of mice in a new study published today in the journal Cancer Research. In the animals, the drug also stopped lung cancer tumours from growing and becoming resistant to treatment. The authors of the research, from Imperial College London, are now planning to take the drug into clinical trials, to establish whether it could offer hope to patients with an inoperable form of lung cancer.
New findings open up to new therapeutic strategies against cancer.
A team of Chinese researchers have for the first time "mended" defective embryos using chemical surgery to free them of a faulty gene that leads to beta thalassemia. Until now this defect was found to be incorrigible caused due to a single misspelling in the DNA code. Beta thalassemia is a dreaded blood disorder wherein the child is unable to make healthy blood needing blood transfusions on a regular basis. The study was published this week in the journal Protein and Cell.
GPC Biotech AG has announced that the Oncologic Drugs Advisory Committee (ODAC) for the U.S. Food and Drug Administration (FDA) recommended (12-0) that the FDA should wait for the final survival analysis of the SPARC trial before deciding whether the satraplatin application is approvable for the treatment of hormone-refractory prostate cancer patients whose prior chemotherapy has failed.
› Verified 2 days ago
| Entity Name | Texas Post Acute Specialists, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609314392 PECOS PAC ID: 9234407255 Enrollment ID: O20170615002605 |
News Archive
Glenmark Pharmaceuticals S.A, a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India, announced today that it has entered into an agreement with Sanofi to grant Sanofi a license for the development and commercialization of GBR 500, a novel monoclonal antibody for the treatment of Crohn's Disease and other inflammatory conditions.
A potential new drug for lung cancer has eliminated tumours in 50% of mice in a new study published today in the journal Cancer Research. In the animals, the drug also stopped lung cancer tumours from growing and becoming resistant to treatment. The authors of the research, from Imperial College London, are now planning to take the drug into clinical trials, to establish whether it could offer hope to patients with an inoperable form of lung cancer.
New findings open up to new therapeutic strategies against cancer.
A team of Chinese researchers have for the first time "mended" defective embryos using chemical surgery to free them of a faulty gene that leads to beta thalassemia. Until now this defect was found to be incorrigible caused due to a single misspelling in the DNA code. Beta thalassemia is a dreaded blood disorder wherein the child is unable to make healthy blood needing blood transfusions on a regular basis. The study was published this week in the journal Protein and Cell.
GPC Biotech AG has announced that the Oncologic Drugs Advisory Committee (ODAC) for the U.S. Food and Drug Administration (FDA) recommended (12-0) that the FDA should wait for the final survival analysis of the SPARC trial before deciding whether the satraplatin application is approvable for the treatment of hormone-refractory prostate cancer patients whose prior chemotherapy has failed.
› Verified 2 days ago
| Entity Name | Pai Participant 9 Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679135420 PECOS PAC ID: 7113254277 Enrollment ID: O20190812003650 |
News Archive
Glenmark Pharmaceuticals S.A, a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India, announced today that it has entered into an agreement with Sanofi to grant Sanofi a license for the development and commercialization of GBR 500, a novel monoclonal antibody for the treatment of Crohn's Disease and other inflammatory conditions.
A potential new drug for lung cancer has eliminated tumours in 50% of mice in a new study published today in the journal Cancer Research. In the animals, the drug also stopped lung cancer tumours from growing and becoming resistant to treatment. The authors of the research, from Imperial College London, are now planning to take the drug into clinical trials, to establish whether it could offer hope to patients with an inoperable form of lung cancer.
New findings open up to new therapeutic strategies against cancer.
A team of Chinese researchers have for the first time "mended" defective embryos using chemical surgery to free them of a faulty gene that leads to beta thalassemia. Until now this defect was found to be incorrigible caused due to a single misspelling in the DNA code. Beta thalassemia is a dreaded blood disorder wherein the child is unable to make healthy blood needing blood transfusions on a regular basis. The study was published this week in the journal Protein and Cell.
GPC Biotech AG has announced that the Oncologic Drugs Advisory Committee (ODAC) for the U.S. Food and Drug Administration (FDA) recommended (12-0) that the FDA should wait for the final survival analysis of the SPARC trial before deciding whether the satraplatin application is approvable for the treatment of hormone-refractory prostate cancer patients whose prior chemotherapy has failed.
› Verified 2 days ago
| Entity Name | Reliant Md Medical Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952865495 PECOS PAC ID: 2466871207 Enrollment ID: O20200929001482 |
News Archive
Glenmark Pharmaceuticals S.A, a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India, announced today that it has entered into an agreement with Sanofi to grant Sanofi a license for the development and commercialization of GBR 500, a novel monoclonal antibody for the treatment of Crohn's Disease and other inflammatory conditions.
A potential new drug for lung cancer has eliminated tumours in 50% of mice in a new study published today in the journal Cancer Research. In the animals, the drug also stopped lung cancer tumours from growing and becoming resistant to treatment. The authors of the research, from Imperial College London, are now planning to take the drug into clinical trials, to establish whether it could offer hope to patients with an inoperable form of lung cancer.
New findings open up to new therapeutic strategies against cancer.
A team of Chinese researchers have for the first time "mended" defective embryos using chemical surgery to free them of a faulty gene that leads to beta thalassemia. Until now this defect was found to be incorrigible caused due to a single misspelling in the DNA code. Beta thalassemia is a dreaded blood disorder wherein the child is unable to make healthy blood needing blood transfusions on a regular basis. The study was published this week in the journal Protein and Cell.
GPC Biotech AG has announced that the Oncologic Drugs Advisory Committee (ODAC) for the U.S. Food and Drug Administration (FDA) recommended (12-0) that the FDA should wait for the final survival analysis of the SPARC trial before deciding whether the satraplatin application is approvable for the treatment of hormone-refractory prostate cancer patients whose prior chemotherapy has failed.
› Verified 2 days ago
| Entity Name | Openloop Healthcare Partners Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245820661 PECOS PAC ID: 2668871898 Enrollment ID: O20210527001998 |
News Archive
Glenmark Pharmaceuticals S.A, a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India, announced today that it has entered into an agreement with Sanofi to grant Sanofi a license for the development and commercialization of GBR 500, a novel monoclonal antibody for the treatment of Crohn's Disease and other inflammatory conditions.
A potential new drug for lung cancer has eliminated tumours in 50% of mice in a new study published today in the journal Cancer Research. In the animals, the drug also stopped lung cancer tumours from growing and becoming resistant to treatment. The authors of the research, from Imperial College London, are now planning to take the drug into clinical trials, to establish whether it could offer hope to patients with an inoperable form of lung cancer.
New findings open up to new therapeutic strategies against cancer.
A team of Chinese researchers have for the first time "mended" defective embryos using chemical surgery to free them of a faulty gene that leads to beta thalassemia. Until now this defect was found to be incorrigible caused due to a single misspelling in the DNA code. Beta thalassemia is a dreaded blood disorder wherein the child is unable to make healthy blood needing blood transfusions on a regular basis. The study was published this week in the journal Protein and Cell.
GPC Biotech AG has announced that the Oncologic Drugs Advisory Committee (ODAC) for the U.S. Food and Drug Administration (FDA) recommended (12-0) that the FDA should wait for the final survival analysis of the SPARC trial before deciding whether the satraplatin application is approvable for the treatment of hormone-refractory prostate cancer patients whose prior chemotherapy has failed.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Kelli Renee White, FNP-BC 1924 Pine St 504, Abilene, TX 79601-2452 Ph: (325) 670-4730 | Mrs Kelli Renee White, FNP-BC 1924 Pine St, Suite 401c, Abilene, TX 79601-2451 Ph: (325) 670-4020 |
News Archive
Glenmark Pharmaceuticals S.A, a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India, announced today that it has entered into an agreement with Sanofi to grant Sanofi a license for the development and commercialization of GBR 500, a novel monoclonal antibody for the treatment of Crohn's Disease and other inflammatory conditions.
A potential new drug for lung cancer has eliminated tumours in 50% of mice in a new study published today in the journal Cancer Research. In the animals, the drug also stopped lung cancer tumours from growing and becoming resistant to treatment. The authors of the research, from Imperial College London, are now planning to take the drug into clinical trials, to establish whether it could offer hope to patients with an inoperable form of lung cancer.
New findings open up to new therapeutic strategies against cancer.
A team of Chinese researchers have for the first time "mended" defective embryos using chemical surgery to free them of a faulty gene that leads to beta thalassemia. Until now this defect was found to be incorrigible caused due to a single misspelling in the DNA code. Beta thalassemia is a dreaded blood disorder wherein the child is unable to make healthy blood needing blood transfusions on a regular basis. The study was published this week in the journal Protein and Cell.
GPC Biotech AG has announced that the Oncologic Drugs Advisory Committee (ODAC) for the U.S. Food and Drug Administration (FDA) recommended (12-0) that the FDA should wait for the final survival analysis of the SPARC trial before deciding whether the satraplatin application is approvable for the treatment of hormone-refractory prostate cancer patients whose prior chemotherapy has failed.
› Verified 2 days ago
Jewel Monique Trancoso, APRN, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2600 Ivanhoe Ln Apt 204, Abilene, TX 79605 Phone: 325-513-7293 | |
Brandon M. Goetz, N.P. Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1900 Pine St, Abilene, TX 79601 Phone: 325-670-2151 Fax: 405-321-4603 | |
Ana Maria Argumaniz, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1749 Pine St, Abilene, TX 79601 Phone: 325-696-0600 | |
Lauren Brooke Terrell, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 950 N 19th St Ste 200, Abilene, TX 79601 Phone: 325-670-5320 Fax: 325-670-5324 | |
Ms. Elizabeth Webber, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 818 Lexington Ave, Abilene, TX 79605 Phone: 325-696-0212 | |
Richard Sankara Musonera, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1749 Pine St, Abilene, TX 79601 Phone: 325-696-0600 Fax: 325-676-3873 | |
Bailey Ann Estes, APRN-CNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1210 N 18th St, Abilene, TX 79601 Phone: 325-207-4734 |